Protagonist Therapeutics, Inc. (PTGX) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Newark, CA, 미국. 현재 CEO는 Dinesh V. Patel.
PTGX 을(를) 보유 IPO 날짜 2016-08-11, 124 명의 정규직 직원, 에 상장 NASDAQ Global Market, 시가총액 $6.68B.
Protagonist Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing peptide-based therapeutic drugs for hematology, blood disorders, and inflammatory and immunomodulatory diseases. The company's clinical pipeline includes rusfertide (PTG-300), an injectable hepcidin mimetic in Phase II trials for polycythemia vera and hereditary hemochromatosis; PN-943, an oral integrin antagonist peptide in Phase II development for inflammatory bowel disease; and PN-235, an orally delivered interleukin-23 receptor antagonist for IBD and other indications. Protagonist maintains a license and collaboration agreement with Janssen Biotech, Inc. and operates from its headquarters in Newark, California.
